LXEOHealthcare · BiotechnologyThe 9 Wall Street analysts covering Lexeo Therapeutics, Inc. hold a median 12-month price target of $20 — +523.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Lexeo Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (81): Sales and profits are climbing, and climbing faster than before.
Value (23): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LXEO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +523.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Sept 2026 | Leerink Partners | Maintains | Outperform | $15 |
| 25 June 2026 | JP Morgan | Maintains | Overweight | $12 → $9.00 |
| 25 June 2026 | JP Morgan | Maintains | Overweight | — |
| 11 May 2026 | Chardan Capital | Maintains | Buy | — |
| 13 Jan 2026 | Chardan Capital | Maintains | Buy | — |
| 13 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Dec 2025 | Raymond James | Initiates | Strong Buy | — |
| 11 Dec 2025 | Chardan Capital | Maintains | Buy | — |
| 1 Dec 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 20 Nov 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 6 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 5 Nov 2025 | Chardan Capital | Maintains | Buy | $17 |
| 21 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Oct 2025 | Guggenheim | Initiates | Buy | — |
| 7 Oct 2025 | Chardan Capital | Maintains | Buy | — |
| 7 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Oct 2025 | Leerink Partners | Maintains | Outperform | — |
| 15 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 15 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Aug 2025 | Leerink Partners | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LXEO appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Lexeo Therapeutics, Inc. returned −60.0% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 85% of US stocks
Cheaper than 68% of US stocks
Cheaper than 66% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 22% of US stocks
Higher than 15% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lexeo Therapeutics, Inc. has a market value of $271.7M and an enterprise value of $66.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$87.3M.
Diluted earnings per share, trailing twelve months: $−1.15.
Free cash flow in the twelve months to 30 June 2026: −$88.7M.
Trailing P/E: −1.8×; forward P/E: −2.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Lexeo Therapeutics, Inc. employs 63 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Lexeo Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Lexeo Therapeutics announced it will participate in a fireside chat at Chardan’s 10th Annual Healthcare Conference on October 20, 2026, at 9:30 a.m. ET. The event will be webcast live on the Events & Presentations tab of the company’s investor website.
Why it matters — LXEO watchers can follow the company’s conference participation through the announced live webcast.
Lexeo Therapeutics announced its abstract for LX2006 has been accepted for an oral presentation at the International Congress of Parkinson's Disease and Movement Disorders 2026 in Seoul, Korea, October 4-8, 2026. The presentation will highlight previously reported data showing early stabilization or improvement in mFARS scores and include new mFARS subscore analyses.
Why it matters — This marks a notable milestone for LXEO as its LX2006 candidate gains visibility and scientific validation through a featured oral presentation at a major international movement disorders congress.
Apertura Gene Therapy will provide Lexeo Therapeutics access to its TfR1 CapX™ AAV capsid technology for a program designed to treat Friedreich ataxia. The collaboration gives Lexeo a next-generation capsid to support delivery of its genetic medicine for this condition.
Why it matters — LXEO watchers would care because gaining access to Apertura's TfR1 CapX™ capsid technology could strengthen Lexeo's Friedreich ataxia program by potentially improving delivery of its genetic medicine, a step that may advance its pipeline in a disease with high unmet need.
Lexeo Therapeutics announced it will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum, scheduled for September 30, 2026 at 9:00am ET. The clinical-stage genetic disease company made the announcement on September 23, 2026.
Why it matters — For LXEO watchers, this participation provides an opportunity for company leadership to present its cardiometabolic/genetic disease programs to the investment community at a major industry forum.
Lexeo Therapeutics, Inc. (LXEO) held a mergers and acquisitions call, and a transcript of that call was published on Seeking Alpha under the headline "Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript." The item consists of the transcript of the M&A call.
Why it matters — A LXEO watcher would care because the transcript provides a record of what the company discussed regarding merger and acquisition matters during the call.
The 9 Wall Street analysts covering Lexeo Therapeutics, Inc. have a median 12-month price target of $20, with estimates ranging from $9 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Lexeo Therapeutics, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lexeo Therapeutics, Inc. 27 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Lexeo Therapeutics, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (81 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +523.1% from the last close, and Ticker Nerd's factor model ranks Lexeo Therapeutics, Inc. 27 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Lexeo Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LXEO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $30 over the next 12 months.
Lexeo Therapeutics, Inc. returned -60.0% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing gene therapy candidates for hereditary and acquired diseases with high unmet medical need.
The most recent item we track (GlobeNewsWire, 8 Oct 2026): "Lexeo Therapeutics to Participate in the Chardan Healthcare Conference". Lexeo Therapeutics announced it will participate in a fireside chat at Chardan’s 10th Annual Healthcare Conference on October 20, 2026, at 9:30 a.m. ET. The event will be webcast live on the Events & Presentations tab of the company’s investor website.
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing gene therapy candidates for hereditary and acquired diseases with high unmet medical need. Lexeo Therapeutics concentrates on genetically defined cardiovascular conditions and APOE4-associated Alzheimer’s disease, using AAV-based programs designed to address the underlying causes of disease. Its current pipeline includes therapies such as LX2006 for Friedreich’s ataxia cardiomyopathy, LX2020 for PKP2-related arrhythmogenic cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer’s disease. The company operates as a biotechnology developer rather than a commercial drug maker, with its work centered on research, clinical development, and advancing precision medicines through early- and mid-stage testing. Based in New York City, Lexeo Therapeutics plays a specialized role in the genetic medicine market by targeting serious conditions where conventional treatments remain limited.
CEO Mr. R. Nolan Townsend M.B.A. · 63 employees · United States · https://www.lexeotx.com
